Autocrine growth inhibition by transforming growth factor β-1 (TGFβ-1) in human neuroendocrine tumour cells

A Wimmel, B Wiedenmann, S Rosewicz

Background and aim: The role of transforming growth factor β-1 (TGFβ-1) in neuroendocrine tumour biology is currently unknown. We therefore examined the expression and biological significance of TGFβ signalling components in neuroendocrine tumours (NETs) of the gastroenteropancreatic (GEP) tract.

Methods: Expression of TGFβ-1 and its receptors, Smads and Smad regulated proteins, was examined in surgically resected NET specimens and human NET cell lines by immunohistochemistry, reverse transcriptase-polymerase chain reaction, immunoblotting, and ELISA. Activation of TGFβ-1 dependent promoters was tested by transactivation assays. Growth regulation was evaluated by cell numbers, soft agar assays, and cell cycle analysis using flow cytometry. The role of endogenous TGFβ was assessed by a TGFβ neutralising antibody and stable transfection of a dominant negative TGFβRII receptor construct.

Results: Coexpression of TGFβ-1 and its receptors TGFβRI and TGFβRII was detected in 67% of human NETs and in all three NET cell lines examined. NET cell lines expressed the TGFβ signal transducers Smad 2, 3, and 4. In two of the three cell lines, TGFβ-1 treatment resulted in transactivation of a TGFβ responsive reporter construct as well as inhibition of c-myc and induction of p21WAF1 expression. TGFβ-1 inhibited anchorage dependent and independent growth in a time and dose dependent manner in TGFβ-1 responsive cell lines. TGFβ-1 mediated growth inhibition was due to G1 arrest without evidence of induction of apoptosis. Functional inactivation of endogenous TGFβ revealed the existence of an autocrine antiproliferative loop in NET cells.

Conclusions: Neuroendocrine tumour cells of the gastroenteropancreatic tract are subject to paracrine and autocrine growth inhibition by TGFβ-1, which may account in part for the low proliferative index of this tumour entity.

Neuroendocrine tumours (NETs) of the gastroenteropancreatic tract (GEP) are rare and originate from a pluripotent stem cell of the diffuse endocrine system of the pancreas and gut. They are classified according to their ontogenetic origin into fore, mid, and hindgut NETs. GEP-NETs are predominantly slow progressing and may grow for months to years without overt clinical symptoms. Based on their characteristic tumour biological phenotype, they have also been referred to as “cancer in slow motion”.

The molecular mechanisms responsible for the slowly proliferating phenotype of NETs are poorly understood. To date, genetic analysis of NETs has not revealed a particular difference from other rapidly growing gastrointestinal tumours which could account for this phenomenon. It therefore appears likely that growth factors or cytokines may be involved in growth regulation of NET cells.

In this context, several growth factors and cytokines are secreted by NET cells, including transforming growth factor β (TGFβ). The TGFβ family consists of three members (TGFβ1–3) which act as multifunctional proteins regulating growth and differentiation of various cell types. TGFβ-1 elicits its biological response after binding to the type II receptor (TGFβRII) which results in heterodimerisation with the type I receptor (TGFβRI) and its subsequent phosphorylation. Activation of TGFβRII results in phosphorylation of the receptor associated Smad proteins 2 and/or 3 which then form heterodimeric complexes with Smad 4. The Smad complexes are translocated into the nucleus where they operate as transcription factors interacting with TGFβ responsive promoters and cooperate with general transcription factors to regulate transcription of target genes.

One central biological response to TGFβ-1 stimulation is growth inhibition which is due to either G1 cell cycle arrest or induction of apoptosis. This physiological growth restraint by TGFβ-1 is often lost during malignant transformation which might contribute to the malignant phenotype of various cancers. The molecular alterations associated with loss of physiological TGFβ responsiveness on carcinogenesis comprise an elevated expression of TGFβ-1, somatic mutations of the TGFβRII as well as TGFβRI, and loss of function mutations of the Smad genes. All inactivating mutations or loss of expression of the TGFβ signalling pathway components can result in resistance to TGFβ-1 growth inhibition. Currently, we know very little about the expression of the TGFβ/TGFβ receptor system in human NET cells. The current study was therefore designed to investigate the expression and biological relevance of TGFβ signalling components in GEP-NET cells.

Abbreviations: TGFβ-1, transforming growth factor β-1; TGFβRI, TGFβ type I receptor; TGFβRII, TGFβ type II receptor; NET, neuroendocrine tumour; GEP, gastroenteropancreatic; PBS, phosphate buffered saline; PARP, poly(ADP-ribose) polymerase; PCNA, proliferating cell nuclear antigen; RT-PCR, reverse transcriptase- polymerase chain reaction; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; SDS, sodium dodecyl sulphate; EGFP, enhanced green fluorescent protein.
MATERIAL AND METHODS

Materials

Dulbecco’s modified Eagle’s medium, RPMI 1640 medium, and phosphate buffered saline (PBS) were purchased from Gibco BRL (Berlin, Germany), and UltraCulture medium from Bio Whittaker (Verviers, Belgium). Fetal calf serum, trypsin/EDTA, and penicillin/streptomycin were from Biochrom (Berlin, Germany). Recombinant human TGFβ-1, TGFβ-2, TGFβ-3, human TGFβ-1 immunoassay, and pan-specific TGFβ antibody (neutralising the biological activity of TGFβ) were from R&D systems (Wiesbaden, Germany). The following antibodies were purchased: anti-poly(ADP ribose) polymerase (PARP) antibody from Calbiochem/Oncogene Research (Bad Soden, Germany); c-myc and Smad 2/3 from BD PharMingen (Heidelberg, Germany); Smad 4/DPC4 and Smad3 from Upstate Biotechnology (Lake Placid, USA); proliferating cell nuclear antigen (PCNA), TGFβ-1 (does not cross react with TGFβ-2 and TGFβ-3), TGFβRI, and TGFβRII from Santa Cruz Biotechnology (Santa Cruz, USA), and secondary antibodies from Dianova (Hamburg, Germany). The chemiluminescence immunoassay for quantification of cell proliferation, based on measurement of BrdU incorporation during DNA synthesis, was from Roche Diagnostics (Mannheim, Germany). Reagents for western blotting were purchased from BioRad Laboratories (Munich, Germany), and enhanced chemiluminescence and polyvinyl difluoride membranes from NEN (Köln, Germany). Superscript reverse transcriptase and oligo(d)T were purchased from GibcoBRL (Eggenstein, Germany); all PCR reagents were from Roche (Mannheim, Germany).

Immunohistochemistry

For our immunohistochemical studies, we used archival tumour material from NET patients resected at Charité University Hospital. All patients gave written informed consent prior to the operation. Tissue sections of resected NETs were formalin fixed and embedded in paraffin. Endogenous peroxidase and non-specific binding were blocked and samples were boiled for 20 minutes in citrate buffer (0.01 M citrate, pH 6.0) to expose the epitopes. Specimens were incubated with antibodies (all antibodies were diluted in PBS with 0.5% bovine serum albumin and 0.5% Tween 20) directed against TGFβ-1 (1:100), TGFβRI (1:100), TGFβRII (1:50), or synaptophysin (1:200). For these experiments, we used a monospecific antibody against TGFβ-1, which does not cross react with TGFβ-2 or TGFβ-3. Two independent approaches were used to confirm specificity.

Figure 1  Expression of transforming growth factor β-1 (TGFβ-1) in gastroenteropancreatic neuroendocrine tumours (NETs). Immunostaining with anti-synaptophysin antibody (A, C, E) and anti-TGFβ-1 antibody (B, D, F). Representative results of 12 tumour samples analysed. TGFβ-1 was detected in tumour cells (D, arrows), mesenchyme (B, arrows), or in both cell types (F, arrows), as derived from serial sections stained with synaptophysin to detect NET cells. Original magnifications ×20.
of the observed immunohistochemical staining (serial dilution until signal disappeared and preimmune serum as first antibody which failed to reveal staining).

Immunohistochemical staining was performed according to the peroxidase method using a horseradish peroxidase coupled secondary antibody and 3-amin-9-ethylcarbazole as the chromogen (Vector Laboratories, Burlingame, California, USA). Immunostaining was defined as positive when at least 10% of tumour cells showed specific immunoreactivity.

Cell culture
The following human NET cell lines were used and cultured as previously described: BON cells derived from a human functional neuroendocrine pancreatic tumour, LCC-18 cells derived from a non-functional neuroendocrine colorectal tumour, and QGP cells derived from a non-functional neuroendocrine pancreatic tumour. The human pancreatic carcinoma cell lines BxPc3 and PANC-1 were obtained from the American Type Tissue Culture Collection (Manassas, Virginia, USA). All media contained 100 U/ml penicillin/streptomycin and 2 mM l-glutamine. Cells were maintained in 95% air and 5% CO2 at 37°C.

RNA preparation and RT-PCR
Total RNA was extracted from all cell lines using RNAzol B reagent (WAK Chemie, Bad Soden, Germany), as described in the supplier's manual. cDNA synthesis was performed at 37°C using 1 µg of each deoxynucleotide triphosphate (dNTP), 10% of tumour cells showed specific immunoreactivity.

Table 1

<table>
<thead>
<tr>
<th>Patient No</th>
<th>Sex</th>
<th>NET Tumour origin</th>
<th>Synaptophysin</th>
<th>TGFβ</th>
<th>TGFβRI</th>
<th>TGFβRII</th>
<th>Ki-67 (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>M</td>
<td>Foregut Pancreas</td>
<td>+</td>
<td>T</td>
<td>M</td>
<td>M</td>
<td>&lt;1</td>
</tr>
<tr>
<td>2</td>
<td>F</td>
<td>Foregut Jejunum</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>&lt;1</td>
</tr>
<tr>
<td>3</td>
<td>M</td>
<td>Foregut Pancreas</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>&lt;1</td>
</tr>
<tr>
<td>4</td>
<td>M</td>
<td>Foregut Pancreas</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>5</td>
</tr>
<tr>
<td>5</td>
<td>F</td>
<td>Foregut Pancreas</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>6</td>
<td>M</td>
<td>Midgut Caecum</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>7</td>
<td>M</td>
<td>Midgut Caecum</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>5</td>
</tr>
<tr>
<td>8</td>
<td>F</td>
<td>Midgut Appendix</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>5</td>
</tr>
<tr>
<td>9</td>
<td>M</td>
<td>Midgut Caecum</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>5</td>
</tr>
<tr>
<td>10</td>
<td>M</td>
<td>Hindgut Sigma</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>70</td>
</tr>
<tr>
<td>11</td>
<td>M</td>
<td>Hindgut Sigma</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>40</td>
</tr>
<tr>
<td>12</td>
<td>M</td>
<td>Hindgut Rectum</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>80</td>
</tr>
</tbody>
</table>

+, positive signal; −, no signal; T, tumour; M, mesenchyme; na, not available. Ki-67 proliferation index as detected by immunohistochemistry.

Protein extraction and western blotting
Whole cell extracts were obtained from subconfluent growing cells, and lysed with 1xRIPA buffer (50 mM Tris, pH 7.5; 0.15 M NaCl; 0.25% sodium dodecyl sulphate (SDS); 0.05% deoxycholate; 1% IGEPAL; 1 mM diethioletrio; 3 mg/ml aprotinin; 2 mM leupeptin; 10 µM EDTA). Lysates were harvested, genomic DNA was fragmented, and lysates were incubated for one hour on ice before centrifugation. Supernatants were quantified by a Lowry based assay and equal amounts of each extract were applied to SDS gels. After electrophoresis, SDS gels were transferred to polyvinylidene difluoride membranes. Blots were reacted overnight at 4°C with the respective monospecific antibodies (diluted 1:1000 in 5% non-fat dried milk in 1×PBS with 0.5% Tween). Immunoreactive bands were identified using peroxidase coupled antirabbit or antimouse antibodies and visualised by enhanced chemiluminescence (Amersham) and exposed to x ray films (Kodak, Stuttgart, Germany).

Transient transfection assays
BON cells (2×10⁴), LCC-18 cells (4×10⁴), or QGP cells (1×10⁴) were detached overnight and then transfected with 0.4 µg of the TGFβ sensitive p3TPlux luciferase reporter construct (kindly provided by Jeff Wrana, Toronto, Canada) and 0.01 µg of renilla control reporter construct pRL-TK (Promega, Mannheim, Germany) for four hours with 10 µl Effectene medium for 24 hours under standard conditions in the presence or absence of 10 ng/ml TGFβ-1. Cell extracts were then prepared using the dual luciferase reporter assay system (Promega, Mannheim, Germany). Firefly luciferase and renilla luciferase luminescence were determined using 25 µl of cell lysate and measured for 15 seconds using a Lumat LB 9501 (EG&G Berthold, Bad Wildbad, Germany). Results were normalised to renilla luciferase light production to correct for transfection efficiency.

Growth assays
Cells were plated in 24 well culture dishes at a density of 1.5×10⁴ cells/well and allowed to attach overnight. Medium was then replaced either with or without TGFβ-1 or neutralising TGFβ antibody. At the indicated time points, cells were
Autocrine growth inhibition by TGFβ-1 in tumour cells

**Figure 2** Expression of transforming growth factor β (TGFβ) signalling components in neuroendocrine tumour (NET) cell lines.

(A) NET cell lines express TGFβ type I receptor (TGFβR I) and TGFβ type II receptor (TGFβR II) mRNA transcripts. RT-PCR analysis using primers specifically directed against TGFβR I, TGFβR II, and GAPDH was performed. Alternating lanes represent the results with (+) or without (−) prior reverse transcription to exclude genomic DNA contamination. A 100 bp DNA ladder was used for size determination and the size of the amplicons are indicated. (B) Immunoblots using whole cell extracts (50 µg protein/lane) were performed to determine expression of TGFβR I, TGFβR II, Smad2, Smad3, and Smad4 protein. Immunodetectable proteins migrated at the expected molecular mass, as indicated. (C) TGFβ-1 protein is expressed and secreted in NET cell lines. Cells (2x10⁶) were seeded overnight and cultured in serum free UltraCulture medium for three days. A TGFβ-1 specific EUSA was used to determine TGFβ-1 concentrations in the supernatants of the indicated cell lines and normalised to protein content/ml supernatant. Each experiment was performed in triplicate. (D) NET cell lines express TGFβ-2 and TGFβ-3 mRNA transcripts. RT-PCR analysis using primers specifically directed against TGFβ-2 and TGFβ-3 was performed. Alternating lanes represent the results with (+) or without (−) prior reverse transcription.

Cell proliferation was also assayed by a chemiluminescence immunoassay measuring BrdU incorporation during DNA synthesis: 5x10⁴ cells/well were seeded in a 96 well microtitre plate and allowed to attach overnight. TGFβ-1 or neutralising TGFβ antibody was added and incubated for 72 hours. For the last six hours BrdU was added to the cells. After harvesting the microtitre plate, cells were fixed and DNA was denatured. An anti-BrdU antibody was incubated, binding to the BrdU incorporated in newly synthesised cellular DNA. The immune complexes were detected by the subsequent substrate reaction and chemiluminescence detection was performed using a Microlumat Plus LB 96V (Berthold Technologies, Bad Wildbach, Germany).

**Anchorage independent growth**

Clonal growth of NET cells was examined based on colony formation in agar suspension, as previously described. In brief, 10⁴ cells were plated as a single cell suspension in methylcellulose and incubated over 10 days. Colonies were scored microscopically with an arbitrary cut off set at 30 cells minimum.

**Flow cytometry**

NET cells were fixed with 70% ethanol at −20°C overnight, washed with 1×PBS, and stained with propidium iodide (50 µg/ml) in 1×PBS supplemented with RNase (10 µg/ml) for 30 minutes. Flow cytometry was performed on a FACScan (Beckton Dickinson, Heidelberg, Germany) equipped with CellQuest software, and cellular DNA content was determined for 1x10⁴ cells.

**Measurement of TGFβ-1 in cell cultures**

TGFβ-1 concentrations were assayed by a specific human TGFβ-1 Elisa (R&D Systems) following the manufacturer’s instructions and normalised to protein content.

**Stable transfection of dominant negative TGFβRII**

NET cells were transfected using the Effectene reagent following the manufacturer’s instructions. The expression vector contained a cDNA construct encoding a dominant negative mutant of the TGFβRII fused to enhanced green fluorescent protein (EGFP) (TBRRII- KR/EGFP) or an empty EGFP expression vector as a control (pEGFP-N3) (kindly provided by JY Li, France). TBRRII-KR contains the human TGFβRII cDNA mutated (K277R at position 1167) and deleted for the last 639 bp of its coding region which was inserted into the pEGFP-N3 expression vector upstream and in frame with the EGFP encoding sequence. Transfected cells were kept under G418 selection pressure and expanded. Successful transfection was confirmed by western blotting using an anti-EGFP antibody and fluorescence microscopy.

**Statistical analysis**

All data are shown as mean (SEM) unless otherwise indicated. Statistically significant differences were evaluated by one way analysis of variance (ANOVA). Statistical analysis was performed using GraphPad statistical software (San Diego, CA, USA).
Monospecific antibodies against c-lysates were prepared and subjected to immunoblot analysis using β-TGFβ1 (10 ng/ml (+) for the indicated time points. Whole cell targets in NET cells. NET cell lines were incubated with vehicle (−) or 1 induces endogenous TGFβ1 (*p<0.05). (B) TGFβ in independent experiments, each performed in triplicate, and transfection efficiency. Data represent mean (SEM) of five plasmids and incubated with 10 ng/ml TGFβ1 for the indicated time periods and cell numbers were determined. Values represent mean (SEM) from at least three separate experiments, each conducted in triplicate (*p<0.05).

Figure 3 Transforming growth factor β-1 (TGFβ1) signalling in neuroendocrine tumour (NET) cell lines. (A) TGFβ1 induces transactivation of a TGFβ1 sensitive reporter construct in NET cell lines. Cells were transiently transfected with p3TPlux and renilla plasmids and incubated with 10 ng/ml TGFβ1 for 24 hours. Relative luciferase activity (RLU) was determined and normalised for transfection efficiency. Data represent mean (SEM) of five independent experiments, each performed in triplicate, and determined as fold induction compared with untreated controls (*p<0.05). (B) TGFβ1 induces endogenous TGFβ1 downstream targets in NET cells. NET cell lines were incubated with vehicle (−) or TGFβ1 (10 ng/ml (+) for the indicated time points. Whole cell lysates were prepared and subjected to immunoblot analysis using monospecific antibodies against c-myc and p21WAF1. Monospecific proliferating cell nuclear antigen (PCNA) antibody was used to control for equal loading. A representative of three independent experiments is shown.

As expected, synaptophysin, which serves as a marker for neuroendocrine differentiation,3 stained tumour cells positive in all samples investigated. (fig 1A, C, E).

Analysis of TGFβ1 expression revealed eight immunoreactive tumours (corresponding to 66.7% of all; 4/5 foregut (80%), 2/4 midgut (50%), 2/3 hindgut (66.7%)) (fig 1D, E, table 1) and four non-reactive tumours (fig 1B). Expression of TGFβ1 in the surrounding mesenchymal tissue was detectable in eight samples (corresponding to 66.7% of all; 3/5 foregut (60%), 4/4 midgut (100%), 1/3 hindgut (33.3%)) (fig 1B, F); coexpression of TGFβ1 in both tumour and mesenchyme was detected in five samples (corresponding to 62.5% of all; 2/5 foregut (40%), 2/4 midgut (50%), 1/3 hindgut (33.3%)) (fig 1F). When more demanding criteria were applied (for example, 25% and 50% of all tumour cells stained positive), we still observed 50% and 33% TGFβ1-1 positive tumours, respectively.

Likewise, we investigated expression of the two TGFβ1 receptors, TGFβR I and TGFβR II, in the same tumour samples. Tumour cell expression of both receptors was observed in all 12 tumours, indicating that coexpression of TGFβ1-1 and its receptors was a common feature for the majority of NET cells examined (8/12 tumours; 66.7% of all) (table 1). Expression of the two TGFβ1 receptors was also detectable in the surrounding mesenchyme in 6/12 samples for TGFβR I and in 3/12 cases for TGFβR II; furthermore, five tumour samples demonstrated coexpression of TGFβR I and TGFβR II in the surrounding mesenchyme. It is noteworthy that the surrounding tumour mesenchyme also demonstrated coexpression of TGFβ1-1 and its receptors TGFβR I and TGFβR II in 3/12 cases (25%) (table 1).

Expression of TGFβ signalling components in human NET cell lines

We next attempted to identify representative human neuroendocrine cell lines as a suitable in vitro model to study the biological effects of TGFβ1. For this purpose we used the human

---

### Table: Expression of TGFβ-1 and its receptors in human NETs

<table>
<thead>
<tr>
<th>NET Sample</th>
<th>TGFβ1 Expression</th>
<th>TGFβR I Expression</th>
<th>TGFβR II Expression</th>
</tr>
</thead>
<tbody>
<tr>
<td>Foregut 1</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Foregut 2</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Midgut 1</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Midgut 2</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Hindgut 1</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Hindgut 2</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
</tbody>
</table>

---

Results

Expression of TGFβ-1 and its receptors in human NETs

Twelve NET samples including five cases from the foregut, four cases from the midgut, and three cases from the hindgut were examined by immunohistochemistry using rabbit monospecific antibodies against synaptophysin, TGFβ1, TGFβR I, and TGFβR II.
neuroendocrine cell lines BON, LCC-18, and QGP. The exocrine pancreatic cancer cell lines BxPc3 and PANC-1, which have previously been characterised as TGFβ1 sensitive, were used as positive controls. By RT-PCR, we were able to detect mRNA expression of TGFβ1 and TGFβR II in all (5/5) cell lines (fig 2A).

Western blot analyses of whole cell extracts revealed expression of the respective receptor proteins. We detected TGFβR I (53 kDa) and TGFβR II (70 kDa) in all cell lines (5/5), thereby confirming the results obtained by RT-PCR (fig 2B).

We next investigated expression of the Smad proteins which act as TGFβ1 downstream effectors. Analysis of whole cell extracts demonstrated Smad2 in all investigated cell lines. The Smad3 antibody detected a protein migrating at the expected size of approximately 50 kDa in all cell lines and the Smad4 antiserum detected a band at the expected size of 73 kDa in all neuroendocrine cell lines (3/3) and PANC-1 cells. In contrast, no Smad4 protein was detected in BxPc3 cells, which were previously described as devoid of Smad4 expression (fig 2B). We next evaluated synthesis and secretion of TGFβ in all cell lines using a human TGFβ specific ELISA. Considerable amounts of TGFβ1 were detectable in supernatants of all five cell lines investigated (fig 2C), albeit in various concentrations, varying from 87.9 pg/ml (LCC-18) to 235.5 pg/ml (BxPc3). By RT-PCR analysis we were also able to detect TGFβ-2 and TGFβ-3 mRNA expression in all three NET cell lines (fig 2D). These data suggest that the NET cell lines reflect the majority of human NETs in vivo with respect to coexpression of TGFβ1 and its receptors.

TGFβ1 signalling in NET cell lines
To verify the functional integrity of TGFβ1 signalling in NET cell lines, transactivation of a TGFβ responsive luciferase reporter construct was evaluated in transient transfection assays. TGFβ1 treatment resulted in significant transactivation of the reporter construct in BON and LCC-18 cell lines, but not in QGP cells (fig 3A).

To further confirm TGFβ1 mediated regulation of endogenous downstream targets for TGFβ1, we investigated expression of c-myc and p21WAF1/CDKN1A. In BON and LCC-18 cells, TGFβ1 treatment resulted in a profound time dependent downregulation of c-myc which was paralleled by induction of p21WAF1 expression compared with untreated controls (fig 3B). In accordance with the transactivation studies, TGFβ1 treatment had no effect on c-myc or p21WAF1 expression in QGP cells, suggesting that this cell line is resistant to TGFβ1 treatment although signalling components were detectable (fig 3B).

TGFβ1 inhibits growth in NET cell lines
We next addressed the question of whether TGFβ1 inhibits growth in human NET cells. TGFβ1 treatment resulted in a significant time dependent inhibition of proliferation in BON and LCC-18 cells but QGP cells were not growth inhibited (fig 4). Whereas BON cells revealed a rather dramatic growth inhibition in response to TGFβ1, LCC-18 cells were moderately growth inhibited, comparable with the growth inhibition observed in PANC-1 cells which have previously been characterised as a TGFβ1 sensitive pancreatic cancer cell line. The differential TGFβ1 sensitivity was reflected by dose-response experiments (fig 5). Half maximal concentrations required for growth inhibition were in the range of 0.1 ng/ml in BON cells whereas 10 ng/ml TGFβ1 were required to achieve significant growth inhibition in LCC-18 cells. Again, QGP cells were TGFβ1 resistant at concentrations of up to 50 ng/ml of the cytokine (fig 5). TGFβ2 and TGFβ3 also acted as growth inhibitors in BON cells but were less potent compared with the antiproliferative effects observed for TGFβ1 (fig 5).

Anchorage independent growth represents a sensitive surrogate marker for tumour growth in vivo. We therefore evaluated the effects of TGFβ1 on colony formation in NET
The growth factor β-1 (TGFβ-1) inhibits anchorage independent growth of human neuroendocrine tumour cells. A single cell agar suspension containing 10^5 cells was incubated with 10 ng/ml TGFβ-1 for 10 days and colonies > 30 cells were then counted and expressed as a percentage of untreated controls. Data represent mean (SEM) from at least three independent experiments, each conducted in triplicate (*p<0.05).

**Figure 6**

In an independent approach, we stably transfected a dominant negative TGFβ receptor (dn-TGFβR) into BON cells. Expression was verified by membrane localisation of the transfected GFP tagged protein (fig 8B). Compared with mock transfected controls, inhibition of endogenous TGFβRII mediated growth inhibition (fig 8C). Furthermore, the growth stimulatory effect of the neutralising TGFβ antibody was completely abolished (fig 8C), suggesting autocrine growth inhibition by TGFβ1 in this NET cell line.

**Autocrine growth inhibition by TGFβ in NET cell lines**

In view of the antimitogenic effects of exogenous TGFβ-1 in BON and LCC-18 cell lines, we next attempted to discriminate induction of apoptosis from cell cycle regulation as the underlying mechanism. Using cell cycle analysis, we observed that TGFβ-1 treatment resulted in a profound G1 arrest in BON cells compared with untreated controls (fig 7).

In contrast, TGFβ-1 treatment did not increase the subdiploid DNA content or induce PARP cleavage, which is used as an early marker of apoptosis, thereby indicating that induction of apoptosis does not occur in response to TGFβ-1 treatment (fig 7).

**DISCUSSION**

Based on the work of Chaudhry and others, TGFβ isoform expression has been demonstrated in approximately 50% of mesenchymal and/or tumour cells of neuroendocrine neoplasms. In contrast, no information regarding expression of TGFβ receptors was available. Our immunohistochemical analysis extends these important observations in several respects: (i) both TGFβ receptors were expressed in all of the human NET specimens investigated; (ii) coexpression of TGFβ-1 and its receptors was a common phenomenon in human NET cells; and (iii) the surrounding mesenchyme also demonstrated coexpression of TGFβ-1 and its receptors in a considerable percentage. These data are in contrast with the exocrine counterparts of NET disease originating from the same organ. For example, loss of TGFβRII expression by pancreatic ductal tumour cells was reported in approximately 50% of the tumours investigated. Based on our expression study, the majority of human NET cells might therefore reflect a biological target for paracrine and autocrine antimitogenic actions of TGFβ-1.

However, expression of TGFβ-1 and its receptors does not necessarily imply functional integrity of the TGFβ signalling.
pathway because inactivation by mutations or loss of expression of TGFβ signalling components is a common phenomenon during carcinogenesis in many tumours. Therefore, we analysed three human NET cell lines with respect to their integrity of TGFβ signalling. All three cell lines expressed TGFβ-1, TGFβ-2, and TGFβ-3, both TGFβ receptors, as well as the TGFβ signalling components Smad 2, 3, and 4, and therefore reflected the in vivo situation. By transactivation assays as well as expression studies of the well defined TGFβ downstream targets p21WAF1 and c-myc, we determined the functional integrity of TGFβ signalling in BON and LCC-18 cells whereas QGP cells did not respond to TGFβ-1. A potential cause of TGFβ-1 resistance in QGP cells is functionally inactivating mutations of TGFβ signalling components. Furthermore, we observed that QGP cells lack expression of the tumour suppressor gene pRb (data not shown) which is required for TGFβ mediated growth inhibition in most tumour cells.

This observation differs from that in other tumour cell lines of the gastrointestinal tract such as the colon or pancreatic cancer cells which demonstrate genetic inactivation and/or loss of Smad and TGFβ receptor expression in 80–100%, thereby disabling the tumour cells to transduce TGFβ initiated antimitogenic signals.

It has been well documented that TGFβ-1 switches from an inhibitor of tumour cell growth to a stimulator of growth and invasion during carcinogenesis in a variety of tumours. For example, while TGFβ-1 inhibits growth in non-transformed colonocytes, it stimulates proliferation in approximately 50% of colon cancer cell lines. In contrast, despite a fully
transformed phenotype, BON and LCC-18 cells responded to TGFβ-1 treatment with profound growth inhibition, which was observed for anchorage dependent or anchorage independent growth. Furthermore, of the three TGFβ isoforms investigated, TGFβ-1 was the most potent in terms of growth inhibition.

In principle, TGFβ-1 is capable of eliciting its antimitogenic effects by two independent mechanisms: induction of apopto-
sis and G1 cell cycle arrest. Using cell cycle analysis as well as PARP cleavage experiments, we were able to demonstrate that TGFβ-1 mediated growth inhibition in NET cells is based exclusively on G1 arrest whereas no evidence for induction of apoptosis could be demonstrated. Our observation of growth inhibition via G1 cell cycle arrest in NET cells is corroborated by increased expression of the cell cycle inhibitor p21WAF1 and decreased expression of c-myc in response to TGFβ-1 stimulation. This is in contrast with the role of TGFβ-1 in certain colon cancer cells and B-Lymphoma where induction of apoptosis has been demonstrated as the central mechanism of action for growth inhibition in response to TGFβ. These data imply that the underlying mechanisms of TGFβ-mediated growth inhibition are cell and tissue type dependent.

Using two independent experimental approaches we were able to demonstrate that NET cells are subject to an autocrine antimitogenic loop by endogenously produced TGFβ-1. While autocrine growth inhibition is a characteristic feature of TGFβ-1 in non-transformed cells, this autocrine growth inhibition is either lost or even switched to growth stimulation on malignant transformation. For example, TGFβ-1 stimulates proliferation in an autocrine manner in a colon cancer cell line whereas it mediates autocrine growth restraint in non-transformed colononic epithelial cells. These observations are therefore in contrast with the neuroendocrine colonic tumour cell line LCC-18 examined in this study where an autocrine antimitogenic loop by TGFβ-1 was preserved on malignant transformation and again highlights the tissue specific features of TGFβ in malignant NET cells.

In summary, we have provided evidence that human NET cells are subject to paracrine and autocrine growth inhibition by TGFβ-1 which may contribute to the slow growing phenotype observed in the majority of human NET disease.

ACKNOWLEDGEMENTS
SR was supported by grants from DFG, Deutsche Krebshilfe, Wilhelm-Sander Stiftung, Else Kröner-Fresenius Stiftung,Sonnenfeld-Stiftung, and Berliner Krebshilfe.

Authors’ affiliations
A Wimmel, B Wiedemann, S Rosewicz, Medizinische Klinik mit Schwerpunkt Gastroenterologie, Charité, Charité, Augustenburger Platz 1, D-13353, Berlin, Germany

REFERENCES

wigm@gutjnl.com

Downloaded from http://gut.bmj.com/ on April 15, 2017 - Published by group.bmj.com
Autocrine growth inhibition by transforming growth factor \( \beta-1 \) (TGF\( \beta-1 \)) in human neuroendocrine tumour cells

A Wimmel, B Wiedenmann and S Rosewicz

*Gut* 2003 52: 1308-1316
doi: 10.1136/gut.52.9.1308